Back to top
more

Aldeyra Therapeutics (ALDX)

(Delayed Data from NSDQ)

$5.08 USD

5.08
1,038,630

+0.27 (5.61%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $5.08 0.00 (0.00%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics

by Zacks Equity Research

CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.

Kinjel Shah headshot

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

by Kinjel Shah

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

Zacks Equity Research

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Are Medical Stocks Lagging Amgen (AMGN) This Year?

by Zacks Equity Research

Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Zacks Equity Research

Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately.

Zacks Equity Research

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap

by Zacks Equity Research

The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.

Zacks Equity Research

Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how BellRing Brands (BRBR) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Zacks Equity Research

Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) have performed compared to their sector so far this year.

Zacks Equity Research

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

Zacks Equity Research

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why

by Zacks Equity Research

Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.

Zacks Equity Research

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Invest in Aldeyra (ALDX) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.

Zacks Equity Research

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics

by Zacks Equity Research

United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy From a Rebounding Industry

by Kinjel Shah

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

Zacks Equity Research

Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.

Zacks Equity Research

Oracle (ORCL) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Oracle's (ORCL) fiscal second-quarter 2024 performance is expected to have benefited from continued demand for cloud infrastructure services.

Zacks Equity Research

Semtech (SMTC) to Release Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Semtech's (SMTC) third-quarter fiscal 2024 results are expected to reflect solid momentum in the industrial market amid macroeconomic challenges.

Zacks Equity Research

Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?

by Zacks Equity Research

Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

BOX Gears Up to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

BOX's fiscal third-quarter results are likely to reflect strength in content cloud solutions.

Zacks Equity Research

What's in Store for Patterson Companies (PDCO) in Q2 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.

Ekta Bagri headshot

Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More

by Ekta Bagri

Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.

Zacks Equity Research

Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback

by Zacks Equity Research

Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.

Zacks Equity Research

Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Aldeyra Therapeutics, Inc. (ALDX) points to a 107.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate

by Zacks Equity Research

Alderya's (ALDX) shares decline on receiving a complete response letter for an investigational candidate, ADX-2191, treating primary vitreoretinal lymphoma.